WO2023118550A1

WO2023118550A1 - Synbiotic for use in a therapy method

Info

Publication number: WO2023118550A1
Application number: PCT/EP2022/087687
Authority: WO
Inventors: Thomas Francis
Original assignee: AASAYA LifeScience GmbH
Priority date: 2021-12-23
Filing date: 2022-12-23
Publication date: 2023-06-29
Also published as: DE102021134539A1

Abstract

The invention relates to a synbiotic (1) comprising at least one prebiotic (2) and at least one probiotic (3), wherein at least the one prebiotic is a human milk oligosaccharide (HMO).

Description

Synbiotic for use in a therapeutic procedure

Description

The invention relates to a synbiotic with the features of independent patent claim 1, a synbiotic for use in a therapy method with the features of independent patent claim 13 and a method with the features of independent patent claim 15.

The human microbiome includes numerous microorganisms that have a significant impact on metabolism and human health. In this context, the intestinal microbiome is of particular importance, to which numerous other functions are ascribed in addition to the task of food utilization. These functions include the defense against pathogens or the synthesis of vitamins and fatty acids. A disadvantageous change in the intestinal microbiome with intestinal inflammation, malfunctions or a lack of immune system function, obesity, metabolic syndrome, oncological diseases, pancreatic dysfunction and other diseases. Due to hormonal and/or neuronal and/or immunological connections, there is also a direct connection between a healthy intestine or an intact intestinal microbiome and diseases of other organs or organ systems such as the brain, skin or lungs.

The microbiome of the gut is sometimes significantly influenced by diet. Influences such as stress or taking medication, especially antibiotics, can also lead to a negative change in the intestinal microbiome and thus cause or promote diseases. Damage to the intestinal microbiome can also be caused by oral vaccinations. It is known from the prior art that in the context of oral vaccinations, pathogenic bacterial strains are used as carriers for orally administered vaccines in order to overcome the physiological tolerance limit in the intestine and to activate the body's immune system or penetration of the vaccine-coupled bacterial cultures through the intestinal wall to allow. On the one hand, this procedure can result in an uncontrolled immune response of the organism and, on the other hand, a sometimes significant damage to the intestinal mucosa as well as a negative change in the intestinal microbiome.

It is therefore an object of the present invention to at least partially overcome at least one of the disadvantages described above. In particular, the object of the invention is to provide a synbiotic for modulating the human intestinal microbiome, by means of which a composition of the intestinal microbiome of a human organism is improved and/or a deterioration in the composition of the intestinal microbiome of a human organism is prevented. A further object of the invention is to provide a synbiotic by which activation of the human immune system can be achieved in order to improve the effect of drugs, in particular vaccines, administered with the synbiotic, before the synbiotic or after the synbiotic.

The above object is achieved by a synbiotic with the features of independent patent claim 1, a synbiotic for use in a therapy method with the features of independent patent claim 13 and by a method with the features of independent patent claim 15. Further features and details of the invention emerge from the subclaims, the description and the drawings. Features and details that are described in connection with the synbiotic according to the invention naturally also apply in connection with the method according to the invention and vice versa, so that the disclosure of the individual aspects of the invention is or can always be referred to reciprocally.

According to the invention, a synbiotic is provided, comprising at least one prebiotic and at least one probiotic, wherein at least one prebiotic is a human milk oligosaccharide (HMO).

A probiotic is generally understood to mean a preparation, mixture of substances or the like which contains one or more living microorganisms which, if taken in sufficient quantities, provide people with a health-promoting benefit. In particular, in the context of the present invention, the term probiotic refers to a specific type of microorganism. The wording that at least one probiotic is included means in the present case that at least one type of probiotic microorganism is included. In the present case, a microorganism, unless otherwise stated, means a bacterium. The bacterium is preferably a bacterium with protective and/or health-promoting properties in relation to the intestinal microbiome, particularly preferably a bifidobacterium or a lactic acid bacterium.

A prebiotic is generally understood to mean a preparation, mixture of substances or the like which contains one or more, in particular indigestible, substance or substances which have a beneficial effect on the human intestinal microbiome. The beneficial effect can be that a substance serves as a, in particular selective, food source for at least one microorganism, stimulates the growth and/or activity of at least one microorganism or changes the habitat of at least one microorganism in a positive way, in particular with regard to propagation of the microorganism affected. In the present case, a selective food source is understood to mean a food source that can only be used or metabolized as food by one (health-promoting or protective) microorganism or individual (health-promoting or protective) microorganisms. In particular, the term prebiotic in the context of the present invention refers to one specific substance or a specific mixture of substances. The wording that at least one prebiotic is included means in the present case that at least one prebiotic substance is included. A prebiotic can be a preferably indigestible saccharide (carbohydrate). The wording indigestible refers to the fact that the substance or the prebiotic in question does not reach the intestine, preferably the large intestine, of a person after oral intake, not resorbed, in relation to positive effects (e.g. reproduction and/or growth and/or increase in activity). to achieve bacterial cultures located there. Prebiotics also enable the immune system to be activated and the tolerance limit to trigger an immune response in the human organism to be reduced. As a result, the desired immune response of the organism to an administered vaccine can be favored or strengthened in the course of a vaccination.

A synbiotic is generally understood to be a combination of probiotics and prebiotics, which has a positive effect on the health of a human organism. The positive effect can consist, for example, in promoting the growth or activity of health-promoting or protective bacterial strains of the intestinal microbiome and/or in supporting the survival and/or colonization of the probiotic microorganisms supplied by the synbiotic. The concept of a combination does not mean that the prebiotics and probiotics combined in a synbiotic must necessarily be taken or administered at the same time. Simultaneous intake of all components of the synbiotic as well as delayed intake of individual components, in particular the prebiotics and probiotics contained, are conceivable. The time lag between taking the prebiotics of a synbiotic according to the invention and the probiotics of a synbiotic according to the invention can be less than or exactly 15 minutes, preferably less than or exactly 10 minutes, particularly preferably less than or exactly 5 minutes.

Human milk oligosaccharides are components of human breast milk and serve as selective nutrition for protective and/or health-promoting intestinal bacteria, in particular bifidobacteria. Thus, by adding human milk oligosaccharides, the growth or multiplication of health-promoting bacterial strains, in particular bifidobacteria, can be stimulated. The dominance of health-promoting intestinal bacteria, in particular bifidobacteria and/or Lactic acid bacteria in the human gut microbiome hinder colonization of the gut by pathogenic bacteria.

The synbiotic according to the invention combines the positive properties of prebiotics and probiotics with regard to the intestinal microbiome and intestinal health. By adding at least one prebiotic, which is a human milk oligosaccharide, the life span of at least individual microorganisms (probiotics) supplied via the synbiotic according to the invention can be extended and their growth and activity can be stimulated. The same applies to health-promoting or protective bacterial cultures already in the intestine, in particular bifidobacteria. Accordingly, it has been shown that the intestinal microbiome of a human organism can be specifically modulated by the synbiotic according to the invention and the number and activity of health-promoting bacterial cultures in the human intestine can be increased overall. This in turn can be used to treat or prevent various clinical pictures that are associated with a negative change in the intestinal microbiome. Due to immunological, hormonal and/or neuronal connections between the human intestine and other human organs or organ systems such as the brain, heart, lungs or skin, it is also possible to improve the health of these organs or organs by taking the synbiotic according to the invention Influencing organ systems in a positive way. The prebiotic contained in the synbiotic according to the invention also enables the immune system to be activated and the tolerance limit for triggering an immune response in the human organism to be reduced. A synbiotic according to the invention thus offers the advantage that the immune system is not activated by pathogenic but by physiologically compatible components (in particular the prebiotics). In this way, favorable conditions can be created for an adequate immune response of the human organism to a drug administered, in particular with the synbiotic or before the synbiotic or after the synbiotic. Preferably, the medicament can be a vaccine. This results in the advantage of increased tolerability and reduced side effects, while at the same time the drug or vaccination is highly effective.

It can be provided within the scope of the invention that at least one probiotic is a preferably non-pathogenic bifidobacterium and/or that at least one probiotic is a preferably non-pathogenic lactic acid bacterium (lactobacterium). Lactic acid bacteria and bifidobacteria naturally colonize the human intestine, where they have tasks such as supporting and regulating digestion, strengthening the immune system, regulating the pH value in the intestinal environment and increasing antibody production. Here, lactic acid bacteria predominantly colonize the small intestine and bifidobacteria predominantly the large intestine. In particular, a dominance of lactic acid and bifidobacteria in the human intestine can prevent excessive colonization of the same by pathogenic bacteria, strengthen the immune system and protect against infectious diseases.

It is conceivable within the scope of the invention that the synbiotic according to the invention contains several, in particular at least two, at least three, at least four or at least five, different prebiotics and/or several, in particular at least two, at least three, at least four or at least five probiotics different from one another includes. In this context it is conceivable that at least one prebiotic is a saccharide, in particular an indigestible saccharide. It is also conceivable that all the prebiotics contained in the synbiotic according to the invention, in particular indigestible ones, are saccharides. It is also conceivable that at least one probiotic is a preferably non-pathogenic lactic acid bacterium and/or that at least one probiotic is a preferably non-pathogenic bifidobacterium. It can also be provided that all the probiotics contained in the synbiotic according to the invention are bacteria from the group of bifidobacteria and lactic acid bacteria.

Within the scope of the invention it is conceivable that at least one prebiotic is a human milk oligosaccharide from the group 2'-FL (2'-fucosyllactose), LNnT (lacto-N-neotetraose). In particular, the human milk oligosaccharides 2'-FL and LNnT can reduce the risk of infectious diseases because they prevent toxins and pathogens from adhering to the intestinal mucosa and reduce inflammatory reactions of the immune system. It is also conceivable that the synbiotic according to the invention comprises at least two prebiotics, the at least two prebiotics preferably being 2'-FL and LNnt.

Within the scope of the invention it can be advantageous that at least one vitamin is included, in particular one from the group of vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, vitamin B12 is. In other words, it can be provided that the inventive Synbiotic includes at least one vitamin in addition to at least one prebiotic and at least one probiotic. Vitamins are organic compounds that are essential for a human organism, but which the human organism cannot synthesize independently or not to a sufficient extent. Accordingly, vitamins must be ingested in sufficient quantities through food. A vitamin deficiency can therefore occur, among other things, as a result of malnutrition and usually has negative health effects on the human organism. A vitamin deficiency can also be caused by negative changes in the intestinal microbiome. One reason for this can be, for example, taking antibiotics. Vitamins, in particular vitamin A, vitamin D, vitamin E and vitamin K, also contribute to the maintenance and health of mucous membranes, in particular the intestinal mucosa, and thus have a direct effect on the intestinal health of a human organism. Vitamin C is characterized, among other things, by its antioxidant effect. Vitamins B1, B2, B3, B5, B6, B7, B9 and B12 are also of great importance in relation to metabolic functions, digestion and the function of the immune system. The addition of at least one vitamin to the synbiotic according to the invention thus offers the advantage of actively counteracting an existing vitamin deficiency and promoting or preserving the health of the intestinal mucosa and protecting it against pathogenic influences.

It is conceivable within the scope of the invention that at least the vitamins A, D, E, K, C, B1, B2, B3, B5, B6, B7 and B12 are comprised by a synbiotic according to the invention. In other words, it can be provided that the synbiotic according to the invention comprises at least 12 vitamins, the at least 12 vitamins preferably being vitamins A, D, E, K, C, B1, B2, B3, B5, B6, B7 and B12. This results in the advantage of an improved supply of vitamins to the human organism.

Furthermore, it can be provided within the scope of the invention, in particular with regard to a use or ingestion of the synbiotic according to the invention by an adult human, that at least one of the following vitamins is included at least in the specified amount or in the specified amount:

- 1 pg to 800 pg, in particular 200 pg to 600 pg, preferably 400 pg to 500 pg, particularly preferably 400 pg vitamin A,

- 1 pg to 35 pg, in particular 1 pg to 15 pg, preferably 1 pg to 5 pg, particularly preferably 3 pg vitamin D, - 1 g to 270 pg, in particular 1 pg to 100 pg, preferably 5 pg to 30 pg, particularly preferably 9 pg vitamin E,

- 1 pg to 750 pg, in particular 1 pg to 300 pg, preferably 10 pg to 50 pg, particularly preferably 30 pg vitamin K,

- 1 mg to 1700 mg, in particular 1 mg to 800 mg, preferably 40 mg to 150 mg, particularly preferably 80 mg vitamin C,

- 0.1 mg to 22 mg, in particular 0.1 mg to 10 mg, preferably 0.5 mg to 1.5 mg, particularly preferably 1.1 mg vitamin B1,

- 0.1 mg to 28 mg, in particular 0.1 mg to 10 mg, preferably 0.5 mg to 1.7 mg, particularly preferably 1.3 mg vitamin B2,

- 1 mg to 16 mg, in particular 8 mg to 16 mg, preferably 10 mg to 14 mg, particularly preferably 12 mg vitamin B3,

- 1 mg to 60 mg, in particular 1 mg to 20 mg, preferably 2 mg to 10 mg, particularly preferably 5 mg vitamin B5,

- 0.1 mg to 18 mg, in particular 0.1 mg to 8 mg, preferably 0.5 mg to 1.7 mg, particularly preferably 1.2 mg vitamin B6,

- 1 pg to 500 pg, in particular 1 pg to 100 pg, preferably 5 pg to 30 pg, particularly preferably 15 pg vitamin B7,

- 1 pg to 600 pg, in particular 50 pg to 400 pg, preferably 150 pg to 250 pg, particularly preferably 200 pg vitamin B9,

- 0.1 pg to 1500 pg, in particular 0.5 pg to 200 pg, preferably 0.5 pg to 20 pg, particularly preferably 2.5 pg of vitamin B12.

In other words, it is conceivable that the synbiotic according to the invention contains at least one of the vitamins listed above in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of one or more vitamins corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of vitamins already explained and from the point of view of an adequate supply of vitamins to the human organism with regard to the use of the synbiotic according to the invention by an adult . An adult is defined within the scope of the present invention as a person who has reached the age of 11. Furthermore, it can be provided within the scope of the invention, in particular with regard to use or ingestion of the synbiotic by an adult, that at least one of the following vitamins is included at least in the specified amount or in the specified amount:

- 15.38 pg to 12307.69 pg, especially 3076.92 pg to 9230.77 pg, preferably

6153.85 pg to 7692.31 pg, particularly preferably 6153.85 pg of vitamin A per 100 g of the synbiotic,

- 15.38 pg to 538.46 pg, in particular 15.38 pg to 230.77 pg, preferably 15.38 pg to 76.92 pg, particularly preferably 46.15 pg of vitamin D per 100 g of the synbiotic,

- 15.38 pg to 4153.85 pg, in particular 15.38 pg to 1538.46 pg, preferably 76.92 pg to 461.54 pg, particularly preferably 138.46 pg of vitamin E per 100 g of the synbiotic,

- 15.38 pg to 11538.46 pg, especially 15.38 pg to 4615.38 pg, preferably

153.85 pg to 769.23 pg, particularly preferably 461.54 pg vitamin K per 100 g of the synbiotic,

- 15.38 mg to 26153.85 mg, in particular 15.38 mg to 12307.69 mg, preferably 615.38 mg to 2307.69 mg, particularly preferably 1230.77 mg of vitamin C per 100 g of the synbiotic,

- 1.54 mg to 338.46 mg, in particular 1.54 mg to 153.85 mg, preferably 7.69 mg to 23.08 mg, particularly preferably 16.92 mg of vitamin B1 per 100 g of the synbiotic,

- 1.54 mg to 430.77 mg, in particular 1.54 mg to 153.85 mg, preferably 7.69 mg to 26.15 mg, particularly preferably 20 mg of vitamin B2 per 100 g of the synbiotic,

- 15.38 mg to 246.15 mg, in particular 123.08 mg to 246.15 mg, preferably 153.85 mg to 215.38 mg, particularly preferably 184.62 mg of vitamin B3 per 100 g of the synbiotic,

- 15.38 mg to 923.08 mg, in particular 15.38 mg to 307.69 mg, preferably 30.77 mg to 153.85 mg, particularly preferably 76.92 mg of vitamin B5 per 100 g of the synbiotic,

- 1.54 mg to 276.92 mg, in particular 1.54 mg to 123.08 mg, preferably 7.69 mg to 26.15 mg, particularly preferably 18.46 mg of vitamin B6 per 100 g of the synbiotic,

- 15.38 pg to 7692.31 pg, in particular 15.38 pg to 1538.46 pg, preferably 76.92 pg to 461.54 pg, particularly preferably 230.77 pg of vitamin B7 per 100 g of the synbiotic, - 15.38 g to 9230.77 pg, in particular 769.23 pg to 6153.85 pg, preferably 2307.69 pg to 3846.15 pg, particularly preferably 3076.92 pg of vitamin B9 per 100 g of the synbiotic,

- 1.54 pg to 23076.92 pg, in particular 7.69 pg to 3076.92 pg, preferably 7.69 pg to 307.69 pg, particularly preferably 38.46 pg of vitamin B12 per 100 g of the synbiotic.

In other words, it is conceivable that the synbiotic contains at least one of the vitamins listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of one or more vitamins corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of vitamins already explained and from the point of view of an adequate supply of vitamins to the human organism with regard to the use of the synbiotic according to the invention by an adult . An adult is defined within the scope of the present invention as a person who has reached the age of 11.

Furthermore, it can be provided within the scope of the invention, in particular with regard to use or ingestion of the synbiotic according to the invention by a child, that at least one of the following vitamins is included at least in the specified amount or in the specified amount:

- 1 pg to 450 pg, in particular 50 pg to 300 pg, preferably 50 pg to 150 pg, particularly preferably 100 pg vitamin A,

- 0.1 pg to 20 pg, in particular 1 pg to 15 pg, preferably 1 pg to 5 pg, particularly preferably 1 pg vitamin D,

- 0.1 pg to 9 pg, in particular 1 pg to 8 pg, preferably 2 pg to 7 pg, particularly preferably 5 pg vitamin E,

- 1 pg to 30 pg, in particular 1 pg to 25 pg, preferably 1 pg to 20 pg, particularly preferably 10 pg vitamin K,

- 1 mg to 45 mg, in particular 1 mg to 35 mg, preferably 1 mg to 20 mg, particularly preferably 10 mg vitamin C,

- 0.1 mg to 0.8 mg, in particular 0.1 mg to 0.7 mg, preferably 0.1 mg to 0.6 mg, particularly preferably 0.5 mg vitamin B1, - 0.1 mg to 0.9 mg, in particular 0.1 mg to 0.7 mg, preferably 0.1 mg to 0.6 mg, particularly preferably 0.5 mg vitamin B2,

- 0.1 mg to 10 mg, in particular 1 mg to 8 mg, preferably 1 mg to 6 mg, particularly preferably 4 mg vitamin B3,

0.1 mg to 4 mg, in particular 0.1 mg to 3 mg, preferably 1 mg to 2 mg, particularly preferably 1.5 mg vitamin B5,

- 0.1 mg to 1 mg, in particular 0.1 mg to 0.8 mg, preferably 0.2 mg to 0.6 mg, particularly preferably 0.5 mg vitamin B6,

- 1 pg to 25 pg, in particular 1 pg to 20 pg, preferably 1 pg to 15 pg, particularly preferably 5 pg vitamin B7,

- 1 pg to 300 pg, in particular 20 pg to 200 pg, preferably 40 pg to 80 pg, particularly preferably 55 pg vitamin B9,

0.1 pg to 2.5 pg, in particular 0.1 pg to 2 pg, preferably 0.1 pg to 1.5 pg, particularly preferably 1 pg of vitamin B12.

In other words, it is conceivable that the synbiotic according to the invention contains at least one of the vitamins listed above in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of one or more vitamins corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of vitamins already explained and from the point of view of an adequate supply of vitamins to the human organism with regard to the use of the synbiotic according to the invention by a child . A child is defined within the scope of the present invention as a person who has not yet reached the age of 11 and preferably has already reached the age of six.

Furthermore, it can be provided within the scope of the invention, in particular with regard to the use or intake of the synbiotic by a child, that at least one of the following vitamins is included at least in the specified amount or in the specified amount:

- 15.38 pg to 6923.08 pg, in particular 769.23 pg to 4615.38 pg, preferably 769.23 pg to 2307.69 pg, particularly preferably 1538.46 pg of vitamin A per 100 g of the synbiotic,

- 1.54 pg to 307.69 pg, in particular 15.38 pg to 230.77 pg, preferably 15.38 pg to 76.92 pg, particularly preferably 15.38 pg of vitamin D per 100 g of the synbiotic, - 1.54 g to 138.46 pg, in particular 15.38 pg to 123.08 pg, preferably 30.77 pg to 107.69 pg, particularly preferably 76.92 pg of vitamin E per 100 g of the synbiotic,

- 15.38 pg to 461.54 pg, in particular 15.38 pg to 384.62 pg, preferably 15.38 pg to 307.69 pg, particularly preferably 153.85 pg of vitamin K per 100 g of the synbiotic,

- 15.38 mg to 692.31 mg, in particular 15.38 mg to 538.46 mg, preferably 15.38 mg to 307.69 mg, particularly preferably 153.85 mg of vitamin C per 100 g of the synbiotic,

- 1.54 mg to 12.31 mg, in particular 1.54 mg to 10.77 mg, preferably 1.54 mg to

9.23 mg, particularly preferably 7.69 mg of vitamin B1 per 100 g of the synbiotic,

- 1.54 mg to 13.85 mg, in particular 1.54 mg to 10.77 mg, preferably 1.54 mg to

9.23 mg, particularly preferably 7.69 mg of vitamin B2 per 100 g of the synbiotic,

- 1.54 mg to 153.85 mg, in particular 15.38 mg to 123.08 mg, preferably 15.38 mg to 92.31 mg, particularly preferably 61.54 mg of vitamin B3 per 100 g of the synbiotic,

- 1.54 mg to 61.54 mg, in particular 1.54 mg to 46.15 mg, preferably 15.38 mg to 30.77 mg, particularly preferably 23.08 mg of vitamin B5 per 100 g of the synbiotic,

- 1.54 mg to 15.38 mg, in particular 1.54 mg to 12.31 mg, preferably 3.08 mg to

9.23 mg, particularly preferably 7.69 mg of vitamin B6 per 100 g of the synbiotic,

- 15.38 pg to 384.62 pg, in particular 15.38 pg to 307.69 pg, preferably 15.38 pg to 230.77 pg, particularly preferably 76.92 pg of vitamin B7 per 100 g of the synbiotic,

- 15.38 pg to 4615.38 pg, in particular 307.69 pg to 3076.92 pg, preferably 615.38 pg to 1230.77 pg, particularly preferably 846.15 pg of vitamin B9 per 100 g of the synbiotic,

- 1.54 pg to 38.46 pg, in particular 1.54 pg to 30.77 pg, preferably 1.54 pg to 23.08 pg, particularly preferably 15.38 pg of vitamin B12 per 100 g of the synbiotic.

In other words, it is conceivable that the synbiotic contains at least one of the vitamins listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of one or more vitamins according to the amounts given above has proven itself with regard to the effects and advantages of vitamins already explained and from the point of view of an adequate supply of the human organism with vitamins, with regard to the use of the synbiotic according to the invention by a child, proved to be advantageous. A child is defined within the scope of the present invention as a person who has not yet reached the age of 11 and preferably has already reached the age of six.

It is also conceivable within the scope of the invention that the synbiotic according to the invention comprises at least two different prebiotics and in particular at least one prebiotic is a saccharide from the group FOS (fructooligosaccharide), GOS (galactooligosaccharide), inulin. In other words, it can be provided that at least one of at least two prebiotics contained in the synbiotic according to the invention is a saccharide from the group FOS, GOS, inulin. Inulin is a mixture of, in particular indigestible, polysaccharides, which is obtained from plants and can be metabolized in particular by bifidobacteria as a selective food source. Accordingly, a supply of inulin has a positive effect on the growth or multiplication of bifidobacteria in the human intestinal microbiome. Fructooligosaccharides (FOS) serve as a selective food source for lactic acid bacteria. Accordingly, a supply of FOS has a positive effect on the growth or multiplication of lactic acid bacteria in the human intestinal microbiome. As a selective food source, galactooligosaccharides (GOS) also have a positive effect on the growth or reproduction of health-promoting bacterial strains in the human intestinal microbiome. In particular, a supply of GOS promotes the growth or multiplication of bifidobacteria and lactic acid bacteria. Thus, the growth or multiplication of health-promoting bacterial strains in the human intestinal microbiome is selectively promoted by supplying FOS and/or GOS and/or inulin, whereby an excessive spread of pathogenic bacterial strains in the human intestinal microbiome can be prevented.

It can be provided within the scope of the invention that the synbiotic according to the invention comprises precisely one prebiotic. It can also be provided that the synbiotic according to the invention comprises at least two or exactly two, in particular at least three or exactly three, preferably at least four different prebiotics, in particular all prebiotics from the group FOS, 2'-FL, LNnt, GOS, inulin are selected.

It can also be provided within the scope of the invention that at least the saccharides FOS, 2′-FL, LNnT, GOS and inulin are included in the synbiotic according to the invention. In other words, it is conceivable that the synbiotic according to the invention comprises at least or exactly five prebiotics, the at least or exactly five prebiotics being FOS, 2′-FL, LNnT, GOS and inulin. The advantages result according to the above statements on the saccharides FOS, 2'-FL, LNnT, GOS and inulin.

In the context of the invention, it is optionally possible, in particular with regard to the use or ingestion of the synbiotic according to the invention by an adult, for at least one of the following prebiotics to be included at least in the specified amount or in the specified amount:

- 1 mg to 15000 mg, in particular 500 mg to 10000 mg, preferably 1000 mg to 2000 mg, particularly preferably 1500 mg FOS,

- 1 mg to 15000 mg, in particular 100 mg to 7500 mg, preferably 300 mg to 1000 mg, particularly preferably 700 mg 2'-FL,

- 1 mg to 15000 mg, in particular 10 mg to 5000 mg, preferably 50 mg to 500 mg, particularly preferably 100 mg LNnT,

- 1 mg to 15000 mg, in particular 500 mg to 10000 mg, preferably 750 mg to 1250 mg, particularly preferably 1000 mg GOS,

- 10 mg to 15000 mg, in particular 500 mg to 10000 mg, preferably 750 mg to 1250 mg, particularly preferably 1000 mg of inulin.

In other words, it is conceivable that the synbiotic according to the invention contains at least one of the prebiotics listed above in an amount which is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of one or more prebiotics corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of the prebiotics already explained and from the point of view of avoiding side effects in relation to the use of the synbiotic according to the invention by an adult.

In the context of the invention, it is optionally possible, in particular with regard to the use or intake of the synbiotic by an adult, for at least one of the following prebiotics to be included at least in the specified amount or in the specified amount: - 15.38 mg to 230769.23 mg, in particular 7692.31 mg to 153846.15 mg, preferably 15384.62 mg to 30769.23 mg, particularly preferably 23076.92 mg FOS per 100 g of the synbiotic,

- 15.38 mg to 230769.23 mg, in particular 1538.46 mg to 115384.62 mg, preferably 4615.38 mg to 15384.62 mg, particularly preferably 10769.23 mg 2'-FL per 100 g of the synbiotic,

- 15.38 mg to 230769.23 mg, in particular 153.85 mg to 76923.08 mg, preferably 769.23 mg to 7692.31 mg, particularly preferably 1538.46 mg LNnT per 100 g of the synbiotic,

- 15.38 mg to 230769.23 mg, in particular 7692.31 mg to 153846.15 mg, preferably 11538.46 mg to 19230.77 mg, particularly preferably 15384.62 mg of GOS per 100 g of the synbiotic,

- 153.85 mg to 230769.23 mg, in particular 7692.31 mg to 153846.15 mg, preferably 11538.46 mg to 19230.77 mg, particularly preferably 15385.62 mg of inulin per 100 g of the synbiotic.

In other words, it is conceivable that the synbiotic contains at least one of the prebiotics listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of one or more prebiotics corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of the prebiotics already explained and from the point of view of avoiding side effects in relation to the use of the synbiotic according to the invention by an adult.

In the context of the invention, it is also conceivable, in particular with regard to the use or ingestion of the synbiotic according to the invention by a child, that at least one of the following prebiotics is included at least in the specified amount or in the specified amount:

- 1 mg to 650 mg, in particular 100 mg to 500 mg, preferably 200 mg to 400 mg, particularly preferably 300 mg FOS,

- 1 mg to 400 mg, in particular 100 mg to 350 mg, preferably 150 mg to 250 mg, particularly preferably 200 mg 2'-FL,

- 1 mg to 100 mg, in particular 10 mg to 80 mg, preferably 40 mg to 60 mg, particularly preferably 50 mg LNnT, - 1 mg to 400 mg, in particular 100 mg to 350 mg, preferably 150 mg to 250 mg, particularly preferably 200 mg GOS,

- 10 mg to 400 mg, in particular 100 mg to 350 mg, preferably 150 mg to 250 mg, particularly preferably 200 mg of inulin.

In other words, it is conceivable that the synbiotic according to the invention contains at least one of the prebiotics listed above in an amount which is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of one or more prebiotics corresponding to the amounts given above has proven to be advantageous with regard to the already explained effects and advantages of the respective prebiotics and from the point of view of avoiding side effects in relation to the use of the synbiotic according to the invention by a child.

In the context of the invention, it is also conceivable, in particular with regard to the use or intake of the synbiotic by a child, that at least one of the following prebiotics is included at least in the specified amount or in the specified amount:

- 15.38 mg to 10000.00 mg, in particular 1538.46 mg to 7692.31 mg, preferably 3076.92 mg to 6153.85 mg, particularly preferably 4615.38 mg FOS per 100 g of the synbiotic,

- 15.38 mg to 6153.85 mg, in particular 1538.46 mg to 5384.62 mg, preferably

2307.69 mg to 3846.15 mg, particularly preferably 3076.92 mg 2'-FL per 100 g of the synbiotic,

- 15.38 mg to 1538.46 mg, in particular 153.85 mg to 1230.77 mg, preferably 615.38 mg to 923.08 mg, particularly preferably 769.23 mg LNnT per 100 g of the synbiotic,

- 15.38 mg to 6153.85 mg, in particular 1538.46 mg to 5384.62 mg, preferably

2307.69 mg to 3846.15 mg, particularly preferably 3076.92 mg GOS per 100 g of the synbiotic,

- 153.85 mg to 6153.85 mg, in particular 1538.46 mg to 5384.62 mg, preferably

2307.69 mg to 3846.15 mg, more preferably 3076.92 mg inulin per 100 g of the synbiotic. In other words, it is conceivable that the synbiotic contains at least one of the prebiotics listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of one or more prebiotics corresponding to the amounts given above has proven to be advantageous with regard to the already explained effects and advantages of the respective prebiotics and from the point of view of avoiding side effects in relation to the use of the synbiotic according to the invention by a child.

It can be provided within the scope of the invention that at least one mineral is included, in particular that at least one mineral from the group calcium, magnesium, iron, zinc, manganese, selenium, chromium, molybdenum is included. Minerals are inorganic nutrients that are essential for a human organism, but which it cannot synthesize independently. Accordingly, minerals must be ingested in sufficient quantities through food. Minerals have important tasks in relation to the human organism. For example, they are part of hormones, bones or blood cells, support the transmission of stimuli and serve to activate enzymes. A lack of minerals can have negative effects on the health of the human organism and result in, for example, tiredness, dizziness, skin changes, osteoporosis or a blood deficiency. The addition of at least one mineral to the synbiotic according to the invention thus offers the advantage of being able to actively counteract an acute mineral deficiency or of being able to generally prevent a mineral deficiency.

It is conceivable within the scope of the invention that at least the minerals calcium, magnesium, iron, zinc, manganese, selenium, chromium and molybdenum are included in a synbiotic according to the invention. In other words, it can be provided that the synbiotic according to the invention comprises at least 8 minerals, the at least 8 minerals preferably being the minerals calcium, magnesium, iron, zinc, manganese, selenium, chromium and molybdenum. This results in the advantage of an improved supply of minerals to the human organism.

Furthermore, it is within the scope of the invention, in particular with regard to use or ingestion of the synbiotic according to the invention by an adult human, conceivable that at least one of the following minerals is included at least in the specified amount or in the specified amount:

- 1 mg to 1000 mg, in particular 400 mg to 1000 mg, preferably 700 mg to 900 mg, particularly preferably 800 mg calcium,

- 1 mg to 250 mg, in particular 100 mg to 250 mg, preferably 200 mg to 250 mg, particularly preferably 250 mg magnesium,

- 1 mg to 14 mg, in particular 5 mg to 14 mg, preferably 10 mg to 14 mg, particularly preferably 14 mg iron,

- 1 mg to 10 mg, in particular 4 mg to 10 mg, preferably 6 mg to 10 mg, particularly preferably 10 mg zinc,

- 0.1 mg to 2 mg, in particular 0.5 mg to 2 mg, preferably 1.5 mg to 2 mg, particularly preferably 2 mg manganese,

- 1 pg to 200 pg, in particular 20 pg to 100 pg, preferably 40 pg to 60 pg, particularly preferably 55 pg selenium.

- 1 pg to 40 pg, in particular 20 pg to 40 pg, preferably 35 pg to 40 pg, particularly preferably 40 pg chromium.

- 1 pg to 350 pg, in particular 10 pg to 200 pg, preferably 30 pg to 100 pg, particularly preferably 50 pg molybdenum.

In other words, it is conceivable that the synbiotic according to the invention contains at least one of the minerals listed above in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of one or more minerals in accordance with the amounts given above has been found to be effective in terms of the effects and advantages of minerals already explained and from the point of view of an adequate supply of minerals to the human organism, in relation to the use of the synbiotic according to the invention by an adult proven beneficial.

Furthermore, it is conceivable within the scope of the invention, in particular with regard to the use or intake of the synbiotic by an adult, that at least one of the following minerals is included at least in the specified amount or in the specified amount:

- 15.38 mg to 15384.62 mg, in particular 6153.85 mg to 15384.62 mg, preferably 10769.23 mg to 13846.15 mg, particularly preferably 12307.69 mg of calcium per 100 g of the synbiotic, - 15.38 mg to 3846.15 mg, in particular 1538.46 mg to 3846.15 mg, preferably 3076.92 mg to 3846.15 mg, particularly preferably 3846.15 mg of magnesium per 100 g of the synbiotic,

- 15.38 mg to 215.38 mg, in particular 76.92 mg to 215.38 mg, preferably 153.85 mg to 215.38 mg, particularly preferably 215.38 mg of iron per 100 g of the synbiotic,

- 15.38 mg to 153.85 mg, in particular 61.54 mg to 153.85 mg, preferably 92.31 mg to 153.85 mg, particularly preferably 153.85 mg of zinc per 100 g of the synbiotic,

- 1.54 mg to 30.77 mg, in particular 7.69 mg to 30.77 mg, preferably 23.08 mg to 30.77 mg, particularly preferably 30.77 mg manganese per 100 g of the synbiotic,

- 15.38 pg to 3076.92 pg, in particular 307.69 pg to 1538.46 pg, preferably 615.38 pg to 923.08 pg, particularly preferably 846.15 pg selenium per 100 g of the synbiotic,

- 15.38 pg to 615.38 pg, in particular 307.69 pg to 615.38 pg, preferably 538.46 pg to 615.38 pg, particularly preferably 615.38 pg chromium per 100 g of the synbiotic,

- 15.38 pg to 5384.62 pg, in particular 153.85 pg to 3076.92 pg, preferably 461.54 pg to 1538.46 pg, particularly preferably 769.23 pg of molybdenum per 100 g of the synbiotic.

In other words, it is conceivable that the synbiotic contains at least one of the minerals listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of one or more minerals corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of minerals already explained and from the point of view of an adequate supply of the human organism with minerals, with regard to the use of the synbiotic according to the invention by an adult .

It is also optionally possible within the scope of the invention, in particular with regard to use or ingestion of the synbiotic according to the invention by a child, for at least one of the following minerals to be included at least in the specified amount or in the specified amount:

- 1 mg to 1000 mg, in particular 400 mg to 1000 mg, preferably 700 mg to 900 mg, particularly preferably 800 mg calcium, - 1 mg to 250 mg, in particular 100 mg to 250 mg, preferably 200 mg to 250 mg, particularly preferably 240 mg magnesium,

- 1 mg to 10 mg, in particular 5 mg to 10 mg, preferably 8 mg to 10 mg, particularly preferably 10 mg iron,

- 1 mg to 8 mg, in particular 2 mg to 6 mg, preferably 4 mg to 6 mg, particularly preferably 6 mg zinc,

- 1 pg to 50 pg, in particular 20 pg to 60 pg, preferably 20 pg to 40 pg, particularly preferably 30 pg selenium,

- 1 pg to 40 pg, in particular 20 pg to 40 pg, preferably 35 pg to 40 pg, particularly preferably 40 pg chromium,

In other words, it is conceivable that the synbiotic according to the invention contains at least one of the minerals listed above in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of one or more minerals in accordance with the amounts specified above has been found to be effective in terms of the effects and advantages of minerals already explained and from the point of view of an adequate supply of minerals to the human organism, in relation to the use of the synbiotic according to the invention by a child proven beneficial.

It is also optionally possible within the scope of the invention, in particular with regard to the use or intake of the synbiotic by a child, for at least one of the following minerals to be included at least in the specified amount or in the specified amount:

- 15.38 mg to 15384.62 mg, in particular 6153.85 mg to 15384.62 mg, preferably 10769.23 mg to 13846.15 mg, particularly preferably 12307.69 mg of calcium per 100 g of the synbiotic,

- 15.38 mg to 3846.15 mg, in particular 1538.46 mg to 3846.15 mg, preferably 3076.92 mg to 3846.15 mg, particularly preferably 3692.31 mg of magnesium per 100 g of the synbiotic, - 15.38 mg to 153.85 mg, in particular 76.92 mg to 153.85 mg, preferably 123.08 mg to 153.85 mg, particularly preferably 153.85 mg of iron per 100 g of the synbiotic,

- 15.38 mg to 123.08 mg, in particular 30.77 mg to 92.31 mg, preferably 61.54 mg to 92.31 mg, particularly preferably 92.31 mg of zinc per 100 g of the synbiotic,

- 15.38 pg to 769.23 pg, in particular 307.69 pg to 923.08 pg, preferably 307.69 pg to 615.38 pg, particularly preferably 461.54 pg selenium per 100 g of the synbiotic,

In other words, it is conceivable that the synbiotic contains at least one of the minerals listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of one or more minerals corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of minerals already explained and from the point of view of an adequate supply of the human organism with minerals, with regard to the use of the synbiotic according to the invention by a child .

In relation to the present invention, it is conceivable that at least one probiotic is a bifidobacterium, in particular that at least one probiotic is a bifidobacterium from the group Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium adolescentis, Bifidobacterium breve. In other words, it is conceivable that at least one probiotic comprised by the synbiotic according to the invention is a bifidobacterium from the above-mentioned group of bifidobacteria. The use of one or more bifidobacteria from the above group has proven to be particularly advantageous in order to achieve the advantages described in connection with bifidobacteria by administering the synbiotic according to the invention in a human organism. It can also be provided that all of the probiotics included in the synbiotic according to the invention are bifidobacteria, in particular bifidobacteria from the above-mentioned group of bifidobacteria.

In the context of the invention, it can be advantageous that at least one probiotic is a lactic acid bacterium, in particular that at least one probiotic is a lactic acid bacterium from the group Lactobacillus rhamnosus GG, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuterii, Lactobacillus bulgaricus, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus thermophilus. In other words, it is conceivable that at least one probiotic comprised by the synbiotic according to the invention is a lactic acid bacterium from the above-mentioned group of lactic acid bacteria. The use of one or more lactic acid bacteria from the above Group has proven to be particularly advantageous in order to achieve the advantages described in connection with lactic acid bacteria by administering the synbiotic according to the invention in a human organism. It can also be provided that all probiotics comprised by the synbiotic according to the invention are lactic acid bacteria, in particular lactic acid bacteria from the above-mentioned group of lactic acid bacteria.

It can be provided within the scope of the invention that all probiotics comprised by the synbiotic from the group Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium adolescentis, Bifidobacterium breve, Lactobacillus rhamnosus GG, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acid ophilus, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuterii, Lactobacillus bulgaricus, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus thermophilus are selected. In particular, the use of at least Bifidobacterium breve and Lactobacillus casei and/or at least Lactobacillus bulgaricus, Bifidobacterium lactis and Streptococcus thermophilus and/or at least Lactobacillus acidophilus, Lactobacillus rhamnosus and Bifidobacterium bifidum results in at least advantages with regard to the prevention of surgical infections and complications . The use of at least Lactobacillus paracasei and Lactobacillus plantarum also proves to be advantageous in this respect. A use of at least Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum and Lactobacillus bulgaricus proves at least Beneficial in relation to the treatment of non-alcoholic fatty liver. The use of at least Lactobacillus plantarum is at least advantageous with regard to the prevention of sepsis, particularly in children. The use of at least Lactobacillus gasseri proves at least beneficial in liver disease. The use of at least Lactobacillus rhamnosus GG offers benefits in the prevention of atopic dermatitis. In the treatment of atopic dermatitis, the use of at least Bifidobacterium infantis has proven beneficial. A combination of at least Bifidobacterium longum and Lactobacillus helveticus may have a beneficial effect on stress-related symptoms. Use of at least Bifidobacterium adolescentis is at least beneficial in treating constipation. A use of at least Lactobacillus helveticus is at least advantageous with regard to nutrient absorption in the human intestine. Use of at least Lactobacillus johnsonii and/or Lactobacillus brevis offers benefits in terms of prevention and treatment of inflammation. Using at least Lactobacillus reuterii offers the advantage of an antimicrobial and antifungal effect.

It is conceivable within the scope of the present invention that the synbiotic according to the invention comprises exactly one probiotic. It can also be provided that the synbiotic according to the invention comprises at least two or exactly two, in particular at least three or exactly three, preferably at least 10, preferably at least 15, particularly preferably at least 20 probiotics, with the probiotics preferably at least partially, in particular all, from the Group Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium adolescentis, Bifidobacterium breve, Lactobacillus rhamnosus GG, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus helveticus, Lac tobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuterii, Lactobacillus bulgaricus, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus thermophilus are selected.

Within the scope of the invention it is conceivable that at least one of the following probiotics is included at least in the specified amount or in the specified amount:

- 1-10 ¹ CFU to 2 10 ¹⁵ CFU, in particular 1 -10 ⁵ CFU to 2 10 ¹² CFU, preferably, 1 -10 ⁸ CFU to 2 10 ¹⁰ CFU, particularly preferably 2.4- 10 ⁹ CFU B. bifidum, - 1 -10 ¹ CFU to 210 ¹⁵ CFU, in particular 1 × 10 ⁵ CFU to 210 ¹² CFU, preferably, 1 × 10 ⁸ CFU to 21O ¹⁰ CFU, particularly preferably 2.410® CFU B. longum,

- 1 -10 ¹ CFU to 210 ¹⁵ CFU, in particular 1·10 ⁵ CFU to 210 ¹² CFU, preferably, 1 -10 ⁸ CFU to 210 ¹⁰ CFU, particularly preferably 2.4-10® CFU B. infantis,

- 1-10 ¹ cfu to 210 ¹⁵ cfu, in particular 1 -10 ⁵ cfu to 210 ¹² cfu, preferably, 1 -10 ⁸ cfu to 210 ¹⁰ cfu, particularly preferably 2.4- 10® cfu B. lactis,

- 1-10 ¹ cfu to 210 ¹⁵ cfu, in particular 1 -10 ⁵ cfu to 210 ¹² cfu, preferably, 1 -10 ⁸ cfu to 210 ¹⁰ cfu, particularly preferably 2.4- 10® cfu B. adolescentis,

- 1-10 ¹ cfu to 210 ¹⁵ cfu, in particular 1 -10 ⁵ cfu to 210 ¹² cfu, preferably, 1 -10 ⁸ cfu to 210 ¹⁰ cfu, particularly preferably 2.4- 10® cfu B. breve,

- 1-10 ¹ CFU to 210 ¹⁵ CFU, in particular 1 -10 ⁵ CFU to 210 ¹² CFU, preferably, 1 -10 ⁸ CFU to 210 ¹⁰ CFU, particularly preferably 2,4- 10® CFU L. rhamnosus GG,

- 1-10 ¹ cfu to 210 ¹⁵ cfu, in particular 1 -10 ⁵ cfu to 210 ¹² cfu, preferably, 1 -10 ⁸ cfu to 210 ¹⁰ cfu, particularly preferably 2.4- 10® cfu L. rhamnosus,

- 1-10 ¹ CFU to 210 ¹⁵ CFU, in particular 1 -10 ⁵ CFU to 210 ¹² CFU, preferably, 1 -10 ⁸ CFU to 21O ¹⁰ CFU, particularly preferably 2,4- 10® CFU L. paracasei,

- 1-10 ¹ CFU to 210 ¹⁵ CFU, in particular 1 -10 ⁵ CFU to 210 ¹² CFU, preferably, 1 -10 ⁸ CFU to 21O ¹⁰ CFU, particularly preferably 2.4- 10® CFU L. acidophilus,

- 1-10 ¹ CFU to 210 ¹⁵ CFU, in particular 1 -10 ⁵ CFU to 210 ¹² CFU, preferably, 1 -10 ⁸ CFU to 21O ¹⁰ CFU, particularly preferably 2,4- 10® CFU L. casei,

- 1-10 ¹ cfu to 210 ¹⁵ cfu, in particular 1 -10 ⁵ cfu to 210 ¹² cfu, preferably, 1 -10 ⁸ cfu to 210 ¹⁰ cfu, particularly preferably 2.4- 10® cfu L. helveticus,

- 1-10 ¹ CFU to 210 ¹⁵ CFU, in particular 1 -10 ⁵ CFU to 210 ¹² CFU, preferably, 1 -10 ⁸ CFU to 210 ¹⁰ CFU, particularly preferably 1-10® CFU L. gasseri,

- 1-10 ¹ cfu to 210 ¹⁵ cfu, in particular 1 -10 ⁵ cfu to 210 ¹² cfu, preferably, 1 ■ 10 ⁸ cfu to 210 ¹⁰ cfu, particularly preferably 1-10® cfu L. johnsonii,

- 1-10 ¹ CFU to 210 ¹⁵ CFU, in particular 1 -10 ⁵ CFU to 210 ¹² CFU, preferably, 1 -10 ⁸ CFU to 210 ¹⁰ CFU, particularly preferably 1 10® CFU L. reuterii,

- 1-10 ¹ CFU to 210 ¹⁵ CFU, in particular 1 -10 ⁵ CFU to 210 ¹² CFU, preferably, 1 -10 ⁸ CFU to 2'10 ¹⁰ CFU, particularly preferably 2.4-10® CFU L. bulgaricus,

- 1-10 ¹ cfu to 210 ¹⁵ cfu, in particular 1 -10 ⁵ cfu to 210 ¹² cfu, preferably, 210 ⁸ cfu to 2'10 ¹ ° cfu, particularly preferably 2.4- 10® cfu L. brevis,

- 1-10 ¹ CFU to 210 ¹⁵ CFU, in particular 1 -10 ⁵ CFU to 210 ¹² CFU, preferably, 1 -10 ⁸ CFU to 2'10 ¹ ° CFU, particularly preferably 2.4- 10® CFU L. fermentum, - 1-10 ¹ cfu to 2 10 ¹⁶ cfu, in particular 1 -10 ⁵ cfu to 2 10 ¹² cfu, preferably, 1 -10 ⁹ cfu to 2 10 ¹¹ cfu, particularly preferably 1 × 10 ¹⁰ cfu L. plantarum,

- 1-10 ¹ CFU to 2 10 ¹⁵ CFU, in particular 1-10 ⁵ CFU to 2 10 ¹² CFU, preferably, 1-10 ⁸ CFU to 2 10 ¹⁰ CFU, particularly preferably 2, 4-10 ⁹ CFU S. thermophilus.

The abbreviation "B." used in the above listing stands for Bifidobacterium. The abbreviation "L." used in the above listing stands for Lactobacillus. The bacterium Lactobacillus bulgaricus is also known as Lactobacillus delbruecki subspecies bulgaricus. The bacterium Lactobacillus paracasei is also known as Lactobacillus paracasei subspecies paracasei. All quantities are given in colony forming units (CFU). A dosage of one or more probiotics corresponding to the amounts specified above has proven to be advantageous with regard to the already explained effects and advantages of probiotic bacterial strains for the human organism and with regard to the avoidance of undesired side effects.

Within the scope of the invention, it is conceivable that at least one of the following probiotics is included at least in the specified amount or in the specified amount:

- 15.38 10 ¹ cfu to 30.77 10 ¹⁵ cfu, in particular 15.38-10 ⁵ cfu to 30.77 10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77 10 ¹⁰ cfu, particularly preferred 36.92 10 ⁹ CFU B. bifidum per 100 g of the synbiotic,

- 15.38 10 ¹ CFU to 30.77 10 ¹⁵ CFU, in particular 15.38- 10 ⁵ CFU to 30.77 10 ¹² CFU, preferably, 15.38- 10 ⁸ CFU to 30.77- 10 ¹ ° CFU, more preferably 36.92-10 ⁹ CFU B. longum per 100 g of synbiotic

- 15.38-10 ¹ cfu to 30.77 10 ¹⁵ cfu, especially 15.38-10 ⁵ cfu to 30.77 10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77 10 ¹⁰ cfu, especially preferably 36.92 10 ⁹ CFU B. infantis per 100 g of the synbiotic,

- 15.38 10 ¹ CFU to 30.77 10 ¹⁵ CFU, in particular 15.38-10 ⁵ CFU to 30.77 10 ¹² CFU, preferably, 15.38-10 ⁸ CFU to 30.77 10 ¹⁰ CFU, particularly preferred 36.92 10 ⁹ CFU B. lactis per 100 g of the synbiotic,

- 15.38 10 ¹ CFU to 30.77 10 ¹⁵ CFU, in particular 15.38-10 ⁵ CFU to 30.77 10 ¹² CFU, preferably, 15.38-10 ⁸ CFU to 30.77 10 ¹⁰ CFU, particularly preferred 36.92 10 ⁹ CFU B. adolescentis per 100 g of the synbiotic,

- 15.38 10 ¹ cfu to 30.77 10 ¹⁵ cfu, in particular 15.38-10 ⁵ cfu to 30.77 10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77 10 ¹⁰ cfu, particularly preferred 36.92 10 ⁹ CFU B. breve per 100 g of the synbiotic, - 15.38 10 ¹ cfu to 30.77 10 ¹⁵ cfu, in particular 15.38-10 ⁵ cfu to 30.77 10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77 10 ¹⁰ cfu, particularly preferred 36.92 10 ⁹ CFU L. rhamnosus GG per 100 g of the synbiotic,

- 15.38 10 ¹ CFU to 30.77 10 ¹⁵ CFU, in particular 15.38-10 ⁵ CFU to 30.77 10 ¹² CFU, preferably, 15.38-10 ⁸ CFU to 30.77 10 ¹⁰ CFU, particularly preferred 36.92 10 ⁹ CFU L. rhamnosus per 100 g of the synbiotic,

- 15.38-10 ¹ cfu to 30.77-10 ¹⁵ cfu, especially 15.38-10 ⁵ cfu to 30.77-10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77-10 ¹⁰ cfu, especially preferably 36.92 10 ⁹ CFU L. paracasei per 100 g of the synbiotic,

- 15.38-10 ¹ cfu to 30.77-10 ¹⁵ cfu, especially 15.38-10 ⁵ cfu to 30.77-10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77-10 ¹⁰ cfu, especially preferably 36.92 10 ⁹ CFU L. acidophilus per 100 g of the synbiotic,

- 15.38-10 ¹ cfu to 30.77-10 ¹⁵ cfu, especially 15.38-10 ⁵ cfu to 30.77-10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77-10 ¹⁰ cfu, especially preferably 36.92 10 ⁹ CFU L. casei per 100 g of the synbiotic,

- 15.38-10 ¹ cfu to 30.77-10 ¹⁵ cfu, especially 15.38-10 ⁵ cfu to 30.77-10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77-10 ¹⁰ cfu, especially preferably 36.92 10 ⁹ CFU L. helveticus per 100 g of the synbiotic,

- 15.38 10 ¹ CFU to 30.77 10 ¹⁵ CFU, in particular 15.38- 10 ⁵ CFU to 30.77 10 ¹² CFU, preferably, 15.38- 10 ⁸ CFU to 30.77- 10 ¹ ° CFU, particularly preferably 15.38- 10 ⁹ CFU L. gasseri per 100 g of the synbiotic,

- 15.38-10 ¹ cfu to 30.77-10 ¹⁵ cfu, especially 15.38-10 ⁵ cfu to 30.77-10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77-10 ¹⁰ cfu, especially preferably 15.38-10 ⁹ CFU L. johnsonii per 100 g of the synbiotic,

- 15.38-10 ¹ cfu to 30.77-10 ¹⁵ cfu, especially 15.38-10 ⁵ cfu to 30.77-10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77-10 ¹⁰ cfu, especially preferably 15.38- 10 ⁹ CFU L. reuterii per 100 g of the synbiotic,

- 15.38-10 ¹ cfu to 30.77-10 ¹⁵ cfu, especially 15.38-10 ⁵ cfu to 30.77-10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77-10 ¹⁰ cfu, especially preferably 36.92 10 ⁹ CFU L. bulgaricus per 100 g of the synbiotic,

- 15.38-10 ¹ cfu to 30.77-10 ¹⁵ cfu, especially 15.38-10 ⁵ cfu to 30.77-10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77-10 ¹⁰ cfu, especially preferably 36.92 10 ⁹ CFU L. brevis per 100 g of the synbiotic, - 15.38 10 ¹ cfu to 30.77 10 ¹⁵ cfu, in particular 15.38-10 ⁵ cfu to 30.77 10 ¹² cfu, preferably, 15.38-10 ⁸ cfu to 30.77 10 ¹⁰ cfu, particularly preferred 36.92 10® KBE L. fermentum per- 100 g of the synbiotic,

- 15.38 10 ¹ cfu to 30.77 10 ¹⁶ cfu, especially 15.38-10 ⁵ cfu to 30.77 10 ¹² cfu, preferably, 15.38-10 ® cfu to 30.77 10 ¹¹ cfu, especially preferred 15.38- 10 ¹⁰ CFU L. plantarum per 100 g of the synbiotic,

- 15.38-10 ¹ CFU to 30.77-10 ¹⁵ CFU, in particular 15.38-10 ⁵ CFU to 30.77-10 ¹² CFU, preferably, 15.38-10 ⁸ CFU to 30.77-10 ¹⁰ CFU, particularly preferably 36 .92 10® CFU S. thermophilus per 100 g of the synbiotic.

In other words, it is conceivable that the synbiotic contains at least one of the probiotics listed above per 100 g of the synbiotic in an amount that is within the value range specified in each case and/or corresponds to a discrete value specified in each case. A dosage of a probiotic or several probiotics corresponding to the amounts given above has proven to be advantageous with regard to the effects and advantages of probiotics already explained.

It can be provided within the scope of the invention that at least one prebiotic, preferably at least two prebiotics, particularly preferably all prebiotics, of the synbiotic are contained in a prebiotic mixture and/or that at least one probiotic, preferably at least two probiotics, particularly preferably all, probiotics of the synbiotic contained in a probiotic mixture. In this context, it can be provided that the prebiotic mixture and the probiotic mixture can be used or taken separately, in particular at different times, or together, in particular simultaneously. In other words, it can be provided that all prebiotics of the synbiotic according to the invention form a prebiotic mixture and all probiotics of the synbiotic according to the invention form a probiotic mixture, with the prebiotic mixture and the probiotic mixture being present separately from one another and being used or taken independently of one another (at different times) or at the same time can. The prebiotic mixture comprises at least one prebiotic and the probiotic mixture comprises at least one probiotic. In addition to at least one prebiotic, the prebiotic mixture can include other components such as at least one vitamin and/or at least one mineral and/or at least one drug. In addition to at least one probiotic, the probiotic mixture can also comprise other components such as at least one medicinal product. Even if in the event of only one prebiotic in the prebiotic mixture and/or only one probiotic in the probiotic mixture there is no mixture in the actual sense, the feature described above relates in particular to a separation of individual and/or all prebiotics and probiotics comprised by the synbiotic from one another in order to ensure independent intake or to be able to use the prebiotics and probiotics of the synbiotic according to the invention. In particular, it can be provided that the prebiotic mixture is taken or used before the probiotic mixture. It is also conceivable that there is a time lag between the intake or use of the prebiotic mixture and the probiotic mixture. The time lag between taking or using the prebiotic mixture and the probiotic mixture can be between 0.5 minutes and 15 minutes, in particular between 1 minute and 10 minutes, preferably between 2 minutes and 10 minutes, particularly preferably between 3 minutes and 5 minutes. This achieves the advantage that a preparatory effect, in particular of the prebiotics, can first be achieved before the remaining components of the synbiotic are added. This can increase the effectiveness of the synbiotic and/or the effectiveness of a drug administered with the synbiotic. The preparatory effect can consist, for example, in stimulating or activating the immune system. For example, as part of a vaccination using the synbiotic according to the invention, activation of the immune system by the prebiotic mixture can first be awaited and only then can the probiotic mixture be administered as a carrier of a vaccine and thus together, in particular at the same time, with the vaccine. As a result, the immune response of the human organism to the vaccine can be increased and thus a higher effectiveness of the vaccination can be achieved. In particular, if the synbiotic is not used as part of a vaccination, but only to modulate the intestinal microbiome, it can also be provided that the prebiotic mixture and the probiotic mixture are used or taken at the same time. Depending on the application, the synbiotic according to the invention can thus be handled optimally. A simultaneous intake of all components of the synbiotic according to the invention is not excluded from the present invention, even in the context of a vaccination.

Furthermore, it can be provided that in addition to at least one prebiotic, at least one vitamin, in particular all vitamins of a synbiotic according to the invention, and/or at least one mineral, in particular all minerals of a synbiotic according to the invention, is/are included in the prebiotic mixture. It is also conceivable that at least one drug, preferably at least one vaccine, is comprised by the synbiotic according to the invention. At least one vaccine can be a live vaccine, an inactivated vaccine, a gene-based vaccine, in particular a DNA vaccine or a vector vaccine or a protein-based vaccine or an RNA vaccine (preferably an mRNA vaccine). The vaccine can be a monovalent or polyvalent vaccine. The vaccine can be a coronavirus vaccine, preferably a Covid-19 vaccine (SARS-CoV-2 vaccine). It is also conceivable that the vaccine is an influenza vaccine.

Provision can be made for at least one vaccine or at least one vaccine component to be included in a probiotic mixture or to be ingested separately from the prebiotics of the synbiotic. It is also conceivable that at least one vaccine or at least one vaccine component is coupled with or contained in at least one probiotic. This can preferably be a polar vaccine component. It is also conceivable that the vaccine only comes into contact with the probiotic mixture or the synbiotic shortly before administration, in particular less than 10 minutes, preferably less than 5 minutes, particularly preferably less than two minutes or less than one minute before administration is brought. It is also conceivable within the scope of the invention that at least one vaccine or at least one vaccine component is contained in a prebiotic mixture. It is also conceivable that at least one vaccine or at least one vaccine component is coupled with at least one prebiotic, in particular molecularly. In particular, it can be provided that at least one vaccine or at least one vaccine component is coupled with a prebiotic from the group inulin, FOS, GOS, preferably with inulin. In this context it is conceivable that at least one vaccine or at least one vaccine component is coupled to functional groups or non-polar carbon-hydrogen (C-H) compounds of at least one prebiotic.

It can therefore be provided within the scope of the invention that different components of a vaccine are coupled to different components of the synbiotic according to the invention. So it is conceivable that at least one vaccine component of a vaccine is coupled to at least one prebiotic and at least one other vaccine component of the vaccine is coupled to at least one probiotic. Also different components of a vaccine can be coupled to different prebiotics or different probiotics of the synbiotic according to the invention.

It can be provided within the scope of the invention that the synbiotic according to the invention is contained in at least one capsule. In this context, it is conceivable that the capsule has several, in particular at least two, chambers, with at least one prebiotic mixture being contained in a first chamber and at least one probiotic mixture being contained in a second chamber. The capsule may be an enteric-coated sustained-release capsule. For this purpose, the capsule can be provided with an enteric coating. The coating can be made from a synthetic polymer, in particular a synthetic polymer from the group consisting of polymethacrylates, vinyl acetate-vinylpyrrolidone copolymers, and polyvinyl acetate phthalates. The coating can also be made of a semi-synthetic polymer, in particular a cellulose derivative. With regard to the present invention, it is also conceivable that the synbiotic according to the invention is contained in two separate capsules, with a first capsule containing at least one prebiotic mixture and a second capsule containing at least one probiotic mixture. Both capsules can be designed identically or differently, in particular in accordance with the above statements with regard to the possible embodiments of a capsule.

It is conceivable according to the invention that the prebiotics and/or the probiotics of the synbiotic according to the invention are at least partially connected to at least one substrate, in particular at least one substrate being a solid or a fluid (liquid or gaseous). In this context it is conceivable that the prebiotics and the probiotics are at least partially connected to the same substrate. It is also conceivable that the prebiotics are associated with at least one first substrate and the probiotics are associated with at least one second substrate, the first substrate being different from the second substrate. Each substrate can be a solid or a fluid, in particular a liquid. In other words, it can be provided that the prebiotics and / or the probiotics of the synbiotic according to the invention are at least partially dissolved in a fluid, in particular in a liquid or a gel, or form an emulsion or suspension with the fluid and thus by a ingestion of the fluid can be administered. The fluid can be a fluid containing sugar or sweetener. This results in the Advantage of simplified intake of the synbiotic or individual components of the synbiotic. It is also conceivable that the prebiotics and/or the probiotics are at least partially connected to a solid or mixture of solids and can be administered by ingesting this solid or mixture of solids. The solid or mixture of solids can be a conventional foodstuff, preferably one containing sugar or sweeteners, in particular a muesli bar, a candy, a lollipop or the like. Administration or intake or use of the synbiotic or individual components of the synbiotic, in particular the prebiotics and/or probiotics, in connection with milk, yoghurt and/or dairy products is also conceivable within the scope of the invention. The combination of the synbiotic according to the invention or parts of the synbiotic according to the invention with foodstuffs or sweeteners has the advantage that intake, in particular for children, is made considerably more pleasant and thus simplified.

It can also be provided within the scope of the invention that at least individual components of the synbiotic can be ingested or used by inhalation. For this purpose, the synbiotic according to the invention or parts thereof can be administered or can be administered in the form of a spray. Dermal, intradermal or intracavitary administration can also be provided. Other modes of administration are not excluded from the scope of the present invention.

It is also conceivable within the scope of the invention that the synbiotic according to the invention is in tablet form. It is conceivable here that all the components of a synbiotic according to the invention are contained in one tablet. Provision can also be made for individual components of a synbiotic according to the invention to be contained in separate tablets. It can be provided that at least all prebiotics of a synbiotic according to the invention, in particular also all vitamins and/or minerals of a synbiotic according to the invention, are included in a first tablet and at least all probiotics of a synbiotic according to the invention are included in a second tablet. In addition to the synbiotic or parts of the synbiotic, a tablet can contain other substances such as fillers (e.g. corn, potato and/or wheat starch, glucose, mannitol or sorbitol) or binding agents (e.g. microcrystalline cellulose, starch, starch paste, cellulose ether, Kollidon or gelatine) contain. A tablet can be designed as a film tablet, which results in the advantage of simplified administration. Furthermore, it can be provided according to the invention that a synbiotic according to the invention is used in a therapy method. In this context, it is conceivable that the therapy method is at least one of the following:

Therapy methods to strengthen the immune system

Therapeutic methods for the prophylaxis and/or treatment of infections

Therapeutic methods for the prophylaxis and/or treatment of complications from infections

Therapeutic methods for the prophylaxis and/or treatment of inflammation

Therapeutic methods for the prophylaxis and/or treatment of oncological diseases

Therapeutic methods for the prophylaxis and/or treatment of diseases of the central nervous system and/or the peripheral nervous system, in particular depression, anxiety, fatigue, long/post-COVID syndrome and/or brain diseases

Therapeutic methods for the prophylaxis and/or treatment of intestinal diseases

Therapeutic methods for the prophylaxis and/or treatment of metabolic syndrome

Therapy methods for the regulation of the hormone balance

Therapeutic methods for the prophylaxis and/or treatment of obesity

Therapeutic methods for the prophylaxis and/or treatment of liver and/or kidney diseases

Therapeutic methods for the prophylaxis and/or treatment of cardiovascular diseases

Therapeutic methods for the prophylaxis and/or treatment of allergies and/or autoimmune diseases, in particular type 1 diabetes mellitus or rare diseases

Therapy methods to reduce and/or completely eliminate antibiotic resistance

Therapeutic methods to increase the immune response after vaccinations vaccinations, in particular the synbiotic is used as a carrier of the vaccine

Therapy methods to support organ system and organ health, in particular heart health, brain health, metabolic health, liver health, kidney health, lung health, skin health and/or human genetics health.

With regard to the use of a synbiotic according to the invention in a therapeutic method for the prophylaxis and/or treatment of infections, it can be provided that it is a therapeutic method for the prophylaxis and/or treatment of coronavirus infections and/or diseases. In particular, it is conceivable that it is a therapeutic method for the prophylaxis and/or treatment of SARS-CoV-2 infections and/or COVID-19 diseases. It is also conceivable that a therapeutic method for the prophylaxis and/or treatment of influenza virus infections and/or diseases is involved. By using a synbiotic according to the invention in the context of a vaccination, the tolerability and the immune response of the human organism to the vaccine can be increased.

In particular with regard to a therapeutic method for the prophylaxis and/or treatment of infections, it can be provided according to the invention that the therapeutic method is a vaccination, with the vaccine being a component of the synbiotic according to the invention and/or at least with parts of the synbiotic according to the invention is administered together. Co-administration does not necessarily mean simultaneous administration. Even a small time lag, in particular a time lag of less than 5 minutes, preferably less than 3 minutes, particularly preferably less than 1 minute, between the administration of the vaccine and the administration of the synbiotic according to the invention or parts thereof, is present as a common Administration understood.

The above object is also achieved by a method according to the invention for the production of a synbiotic, in particular designed according to one of claims 1 to 11, wherein at least the following steps are preferably carried out in the order given: a) determination of at least a first prebiotic amount of a first prebiotic, in particular by weighing, with at least the first prebiotic being a human milk oligosaccharide (HMO), b) determining at least a first probiotic quantity of a first probiotic, in particular by counting colony-forming units. When referring to an amount of prebiotic, the term "amount" refers to a weight. In other words, the term prebiotic amount means an amount by weight of a prebiotic. For example, a prebiotic amount may be 10 mg of a prebiotic such as FOS, GOS, 2'-FL, LNnT, or inulin. When referring to a quantity of probiotics, the term "quantity" refers to a number. In other words, the term probiotic amount means a certain number of colony forming units (CFU) of a probiotic, in particular a bifidobacterium or lactic acid bacterium. For example, a probiotic amount can be 2 10 ⁹ CFU of a bifidobacterium (e.g. Bifidobacterium bifidum).

It can be provided within the scope of the invention that, in particular after steps a) and b), the following method step is additionally carried out: i. preparing a synbiotic mixture by mixing at least the first amount of prebiotic and the first amount of probiotic.

If a synbiotic mixture is produced which contains all the components of the synbiotic, it is conceivable that all the components of the synbiotic, i.e. preferably at least all the prebiotics, vitamins, minerals, probiotics and drugs contained in the synbiotic according to the invention, are mixed with one another in any order to create the synbiotic to make a mixture.

According to the invention it is conceivable that at least the first prebiotic is one from the group 2'-FL, LNnT. The same advantages result as were described in relation to the synbiotic according to the invention.

In relation to the present invention, it is further conceivable that at least the first probiotic is a bifidobacterium or a lactic acid bacterium. In particular, it is conceivable that at least the first probiotic is a bacterium from the group Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium adolescentis, Bifidobacterium breve, Lactobacillus rhamnosus GG, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Lac tobacillus casei, Lactobacillus helveticus, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuterii, Lactobacillus bulgaricus, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus thermophilus. It can also be provided that at least two, at least three, at least four, at least 10, at least 20 or all of the probiotics processed in the method according to the invention are selected from the above list of bacteria. The same advantages result as were described with regard to the use or the above-mentioned probiotics in relation to the synbiotic according to the invention. The wording that a probiotic is a bacterium (e.g. bifidobacterium or lactic acid bacterium) does not represent a quantity. In other words, it is a statement of the type of microorganism in question and not a statement of a quantity.

It is conceivable within the scope of the invention that, in particular in step a), the following method step is additionally carried out: ii. Determination of at least a second prebiotic quantity of a second prebiotic different from the first, in particular at least the second prebiotic being a saccharide, preferably a saccharide from the group 2'-FL, LNnT, FOS, GOS, inulin, particularly preferably a saccharide from the group FOS, GOS, inulin, is, iii. Determination of at least a first vitamin quantity of a first vitamin, in particular by weighing, with at least the first vitamin preferably being one from the group consisting of vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, vitamin B12 is, iv. Determination of at least a first mineral amount of a first mineral, in particular by weighing, with at least the first mineral preferably being one from the group calcium, magnesium, iron, zinc, manganese, selenium, chromium, molybdenum.

In this connection it is conceivable that all the vitamins processed in the method according to the invention are selected from the above-mentioned group of vitamins. It is also conceivable that all of the minerals processed in the method according to the invention are selected from the above-mentioned group of minerals. It is also conceivable that step iii. for at least 5, preferably at least 10, particularly preferably at least or exactly 12, preferably different vitamins. It is also conceivable that step iv. for at least 4, preferably at least 6, particularly preferably at least or exactly 8, preferably different, minerals is carried out. The same advantages result as were described in relation to the synbiotic according to the invention.

It is also conceivable that step ii. for exactly one prebiotic, in particular for at least two or exactly two, preferably for at least three or exactly three, preferably for at least four or exactly 4, in particular different prebiotics. In other words, it can be provided that in step ii. exactly one or at least one, in particular at least two or exactly two, preferably at least 3 or exactly three, preferably at least or exactly 4, amounts of prebiotics can be determined, preferably by weighing, with all prebiotics contained in the synbiotic being different from one another. In combination with the first amount of prebiotics determined in step a), this results in a total of at least two or exactly two, at least three or exactly three, at least four or exactly four, at least five or exactly five amounts of different prebiotics.

It can also be provided within the scope of the invention that, in particular in step b), the following method step is additionally carried out: v. Determination of at least a second probiotic amount of a second probiotic different from the first.

In this regard, it is conceivable that step v. for exactly one probiotic, in particular for at least two or exactly two, preferably at least three or exactly three, preferably at least 9, particularly preferably at least or exactly 19, preferably different, probiotics is carried out. In other words, it can be provided that in step v. exactly one or at least one, in particular at least two or exactly two, preferably at least three or exactly three, preferably at least 9, particularly preferably at least or exactly 19, amounts of probiotics, preferably by counting colony-forming units, are determined, with all probiotics contained in the synbiotic are different from each other. In combination with the first amount of probiotics determined in step b), this results in a total of at least two or exactly two, at least three or exactly three, at least four or exactly four, at least ten, at least twenty or exactly twenty amounts of different probiotics. It is also optionally possible within the scope of the invention that, in particular after steps a) and b), at least the following method step is additionally carried out: vi. Determination of at least a first drug quantity of a first drug, in particular by weighing, with at least the first drug preferably being a vaccine.

It is also optionally possible within the scope of the invention that, in particular after steps a) and b), at least one of the following method steps is additionally carried out: vii. Preparation of a prebiotic mixture by mixing the first amount of prebiotics with at least a second amount of prebiotics and/or at least one amount of vitamins and/or at least one amount of minerals and/or at least one amount of drug, viii. Preparation of a probiotic mixture by mixing the first amount of probiotics with at least a second amount of probiotics and/or at least one amount of drug.

Provision can be made for the prebiotic mixture to be produced by mixing at least all of the prebiotics contained in the synbiotic or the corresponding amounts of prebiotics. It is also conceivable that the probiotic mixture is produced by mixing at least all of the probiotics contained in the synbiotic or the corresponding amounts of probiotics.

In the context of the invention, it is conceivable that step vii. for at least 4, in particular at least or exactly 5, preferably different, prebiotics or amounts of prebiotics is carried out and/or that step viii. for at least 10, in particular at least or exactly 20, preferably different, probiotics or probiotic amounts is carried out. In other words, it can be provided that in step vii. at least 4, in particular at least 5 or exactly 5 amounts of prebiotics are mixed to form a prebiotic mixture. It is also conceivable that in step viii. at least 10, in particular at least or exactly 20 amounts of probiotics are mixed to form a probiotic mixture. The admixture of at least one drug, at least one vitamin or at least one mineral to the prebiotic mixture or the admixture of at least one drug to

A probiotic mixture is conceivable in this context. It is also conceivable within the scope of the invention that, in particular after steps a) and b), preferably as the last method step, the following method step is additionally carried out: ix. Making a synbiotic blend by mixing a prebiotic blend and a probiotic blend.

Further advantages, features and details of the invention result from the following description, in which several exemplary embodiments of the invention are described in detail with reference to the drawings. The features mentioned in the claims and in the description can each be essential to the invention individually or in any combination. while showing

1 shows a simplified representation of a synbiotic according to the invention,

2 shows a simplified representation of a synbiotic according to the invention,

3 shows a simplified representation of a synbiotic according to the invention,

4 shows a simplified representation of a synbiotic according to the invention,

5 shows a simplified representation of a synbiotic according to the invention,

6 shows a simplified representation of a synbiotic according to the invention and

7 shows a method according to the invention for the production of a synbiotic.

1 shows a simplified representation of a synbiotic 1 according to the invention, the synbiotic 1 being contained in a capsule 7 . The capsule has a first chamber 7.1 and a second chamber 7.2, with a first prebiotic 2.1 or a prebiotic mixture 1.1 being contained in the first chamber 7.1 and a first probiotic 3.1 or a probiotic mixture 1.2 being contained in the second chamber 7.2. The first prebiotic 2.1 is a human milk oligosaccharide from the group 2'FL, LNnt. In the present case, the prebiotic mixture comprises only the first prebiotic 2.1 and the probiotic mixture in the present case comprises only the first probiotic 3.1. FIG. 2 shows a simplified representation of a synbiotic 1 according to the invention, the synbiotic 1 being contained in a capsule 7 . The capsule 7 has a first chamber 7.1 and a second chamber 7.2, with a prebiotic mixture 1.1 being contained in the first chamber 7.1 and a probiotic mixture 1.2 being contained in the second chamber 7.2. The chambers 7.1, 7.2 are spatially separated from one another by a partition. The capsule 7 is designed as a capsule 7 that is resistant to gastric juice. The prebiotic mixture 1.1 comprises several different prebiotics 2. In the present case, the prebiotic mixture 1.1 comprises at least a first prebiotic 2.1, a second prebiotic 2.2 and a third prebiotic 2.3, with at least the first prebiotic 2.1 being a saccharide, in particular a saccharide on the group 2'-FL , LNnT, FOG, GOS, inulin, is. Furthermore, the prebiotic mixture 1.1 comprises at least one vitamin 4 and at least one mineral 5. The at least one vitamin 4 is a vitamin from the group of vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, vitamin B1, vitamin B2, vitamin B3, Vitamin B5, Vitamin B6, Vitamin B7, Vitamin B9, Vitamin B12. The at least one mineral 5 is a mineral 5 from the group consisting of calcium, magnesium, iron, zinc, manganese, selenium, chromium and molybdenum. The probiotic mixture 1.2 comprises several different probiotics 3. In the present case, the probiotic mixture 1.2 comprises at least a first probiotic 3.1 and a second probiotic 3.2, the first probiotic 3.1 being a lactic acid bacterium and the second probiotic 3.2 being a bifidobacterium.

Fig. 3 shows a simplified representation of a synbiotic 1 according to the invention. The synbiotic 1 comprises all components of the synbiotic 1 shown in FIG in this case a vaccine.

FIG. 4 shows a simplified representation of a synbiotic 1 according to the invention, the synbiotic 1 corresponding to the synbiotic 1 shown in FIG. 3 with regard to its composition. However, in contrast to FIG. 3, the capsule 7 does not have a partition. Correspondingly, the prebiotic mixture 1.1 and the probiotic mixture 1.2 are not present separately, but rather all the components of the synbiotic 1 are mixed together, so that a synbiotic mixture 1.3 is present.

FIG. 5 shows a simplified representation of a synbiotic 1 according to the invention, the synbiotic 1 corresponding to that shown in FIG. 3 with regard to its composition Synbiotic 1 corresponds. According to the embodiment shown in FIG. 5, however, the prebiotic mixture 1.1 and the probiotic mixture 1.2 are present separately such that the prebiotic mixture 1.1 and the probiotic mixture 1.2 can be handled independently of one another and thus, for example, can be taken at different times. In the present case, the prebiotic mixture 1.1 is contained in a first capsule 7 and the probiotic mixture 1.2 is contained in a second capsule 7. Both capsules 7 are designed as capsules 7 that are resistant to gastric juice.

6 shows a simplified representation of a synbiotic 1 according to the invention, with the prebiotics 2 and the probiotics 3 of the synbiotic 1 being connected to a substrate 8 . In the present case, the substrate is designed as a liquid in which the prebiotics and the probiotics are dissolved or with which the prebiotics and the probiotics form an emulsion or suspension. In the present case, the substrate 8 is a liquid containing a sweetener.

Fig. 7 shows schematically a method 100 according to the invention for the production of a synbiotic 1, wherein at least the following steps are preferably carried out in the order given: a) Determination (110) of at least a first prebiotic amount of a first prebiotic (2.1), in particular by weighing, wherein at least the first prebiotic (2.1) is a human milk oligosaccharide (HMO), b) determining (120) at least a first probiotic quantity of a first probiotic (3.1), in particular by counting colony-forming units.

LIST OF REFERENCE CHARACTERISTICS

synbiotic

prebiotic blend

probiotic blend

Synbiotic Mixture

prebiotic

First prebiotic

Second prebiotic

Third prebiotic

probiotic

First probiotic

Second probiotic

vitamin

minerals

drug

capsule

First chamber

second chamber

substrate

Proceedings

detection

Claims

P a t e n t claims Synbiotic (1) comprising at least one prebiotic (2) and at least one probiotic (3), at least one prebiotic being a human milk oligosaccharide (HMO). Synbiotic (1) according to Claim 1, characterized in that at least one prebiotic (2) is an HMO from the group 2'-FL, LNnT. Synbiotic (1) according to one of the preceding claims, characterized in that at least one vitamin (4) is included, in particular one from the group of vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, vitamin B12 is. Synbiotic (1) according to one of the preceding claims, characterized in that at least the vitamins (4) A, D, E, K, C, B1, B2, B3, B5, B6, B7 and B12 are included. Synbiotic (1) according to one of the preceding claims, characterized in that at least two different prebiotics (2) are included, in particular at least one prebiotic (2) being a saccharide from the group FOS, GOS, inulin. Synbiotic (1) according to one of the preceding claims, characterized in that at least the saccharides FOS, 2'-FL, LNnT, GOS and inulin are included.

- 42 - Synbiotic (1) according to one of the preceding claims, characterized in that at least one mineral (5) is included, in particular that at least one mineral (5) from the group includes calcium, magnesium, iron, zinc, manganese, selenium, chromium, molybdenum is. Synbiotic (1) according to one of the preceding claims, characterized in that at least one probiotic (3) is a bifidobacterium, in particular that at least one probiotic (3) is a bifidobacterium from the group Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium adolescentis , Bifidobacterium breve. Synbiotic according to one of the preceding claims, characterized in that at least one probiotic (3) is a lactic acid bacterium, in particular that at least one probiotic (3) is a lactic acid bacterium from the group Lactobacillus rhamnosus GG, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuterii, Lactobacillus bulgaricus, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus thermophilus. Synbiotic (1) according to one of the preceding claims, characterized in that at least one prebiotic (2) is contained in a prebiotic mixture (1.1) and/or that at least one probiotic (3) is contained in a probiotic mixture (1.2), with preferably the Prebiotic mixture (1.1) and the probiotic mixture (1.2) can be used separately, in particular at different times, or together, in particular simultaneously.

- 43 - Synbiotic (1) according to one of the preceding claims, characterized in that at least one drug (6), preferably a vaccine, is included, with the drug (6) in particular being contained in the probiotic mixture. Synbiotic (1) according to any one of the preceding claims, characterized in that at least one prebiotic (2) and / or at least one probiotic (3) (3) with at least one substrate (8) are at least partially connected, in particular at least one Substrate (8) is a solid or a fluid. Synbiotic (1) for use in a therapy method, wherein the synbiotic (1) is designed according to one of Claims 1 to 12. Synbiotic (1) for use according to claim 13, wherein the therapeutic method is at least one of the following:

Therapy methods to strengthen the immune system

Therapeutic methods for the prophylaxis and/or treatment of infections, in particular coronavirus infections and/or diseases, preferably SARS-CoV-2 infections and/or COVID-19 diseases or influenza virus infections and/or diseases,

Therapeutic methods for the prophylaxis and/or treatment of inflammations Therapeutic methods for the prophylaxis and/or treatment of oncological diseases

Therapeutic methods for the prophylaxis and/or treatment of diseases of the central nervous system and/or the peripheral nervous system, in particular depression, anxiety, fatigue, long/post-COVI D syndrome and/or brain diseases

Therapeutic methods for the prophylaxis and/or treatment of intestinal diseases

Therapeutic methods for the prophylaxis and/or treatment of metabolic syndrome

- 44 - Therapy methods for the regulation of the hormone balance

Methods of therapy for the prophylaxis and/or treatment of obesity Methods of therapy for the prophylaxis and/or treatment of liver and/or kidney diseases

Therapy methods to reduce and/or completely eliminate antibiotic resistance

Therapy methods to increase the immune response after vaccination Therapy methods to support organ system and organ health, in particular heart health, brain health, metabolic health, liver and kidney health, health of the human genome/genetics. Method (100) for producing a synbiotic (1), in particular according to one of claims 1 to 12, wherein at least the following steps are preferably carried out in the order given: a) determination (110) of at least a first prebiotic amount of a first prebiotic (2.1) , in particular by weighing, wherein at least the first prebiotic (2.1) is a human milk oligosaccharide (HMO), b) determining (120) at least a first probiotic quantity of a first probiotic (3.1), in particular by counting colony-forming units. Method (100) according to Claim 15, characterized in that at least the first prebiotic (2) is an HMO from the group 2'-FL, LNnT. The method (100) according to any one of claims 15 to 16, characterized in that at least the first probiotic (3) is one from the group Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium adolescentis, Bifidobacterium breve, Lactobacillus rhamnosus GG, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuterii, Lactobacillus bulgaricus, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus thermophilus. Method (100) according to one of Claims 15 to 17, characterized in that, in particular in step a), at least one of the following method steps is additionally carried out: ii. Determination of at least a second prebiotic amount of a second prebiotic (2.2) different from the first, wherein in particular at least the second prebiotic (2.2) is a saccharide, preferably a saccharide from the group 2'-FL, LNnT, FOS, GOS, inulin . iii. Determination of at least a first vitamin quantity of a first vitamin (4), in particular by weighing, with at least the first vitamin (4) preferably being one from the group of vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, vitamin B12 is, iv. Determining at least a first mineral amount of a first mineral (5), in particular by weighing, with at least the first mineral (5) preferably being one from the group calcium, magnesium, iron, zinc, manganese, selenium, chromium, molybdenum. Method (100) according to one of Claims 15 to 18, characterized in that, in particular in step b), at least the following method step is additionally carried out: v. Determination of at least a second probiotic quantity of a second probiotic different from the first (3.2). Method (100) according to one of Claims 15 to 19, characterized in that, in particular after steps a) and b), at least the following method step is additionally carried out: vi. Determination of at least a first drug quantity of a first drug (6), in particular by weighing, with at least the first drug (6) preferably being a vaccine. Method (100) according to one of Claims 15 to 20, characterized in that, in particular after steps a) and b), at least one of the following method steps is additionally carried out: vii. Preparation of a prebiotic mixture (1.1) by mixing the first amount of prebiotics with at least a second amount of prebiotics and/or at least one amount of vitamins and/or at least one amount of minerals and/or at least one amount of drug, viii. Preparation of a probiotic mixture (1.2) by mixing the first amount of probiotics with at least one second amount of probiotics and/or at least one amount of medicinal product. Method (100) according to one of Claims 15 to 21, characterized in that, in particular after steps a) and b), the following method step is additionally carried out: ix. Preparation of a synbiotic mixture (1.3) by mixing a prebiotic mixture (1.1) and a probiotic mixture (1.2). Method (100) according to any one of claims 15 to 22, characterized in that step vii. for at least 4, in particular at least or exactly 5, preferably different, prebiotics or amounts of prebiotics is carried out and/or that step viii. for at least 10, in particular at least or exactly 20, preferably different, probiotics or probiotic amounts is carried out.

- 47 -